Trial Profile
Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement-mediated Disorders. A Single/Multiple Ascending Dose Phase 1 Study.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Sutimlimab (Primary)
- Indications Autoimmune disorders; Autoimmune haemolytic anaemia; Bullous pemphigoid; Haematological disorders; Renal transplant rejection
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors Bioverativ; True North Therapeutics
- 07 Apr 2021 Status changed from active, no longer recruiting to completed.
- 27 Oct 2020 Status changed from recruiting to active, no longer recruiting.
- 18 Jan 2019 Planned number of patients changed from 98 to 122.